Viral Infections and Cancer Research (VICR) is an international, peer-reviewed, open access journal focusing on the mechanism of viral carcinogenesis. It publishes original research articles, review articles, commentaries and other types of articles with high quality. Viral Infections and Cancer Research (VICR) covers the impact of viral genes on the stability of the host genome, and explores how viruses contribute to the development of cancer by causing host cell genome instability through a variety of mechanisms. Meanwhile, VICR investigates the mechanisms of virus-mediated immune escape and analyses how viral infection alters the tumour microenvironment, including its effects on tumour-associated immune cells, and how it promotes tumour growth and metastasis. In addition, the journal focuses on cancerous processes driven by persistent viral infections, investigating the sustained cellular damage and inflammatory responses triggered by chronic viral infections, which in turn lead to cancer development.

VICR is also dedicated to core research areas covering multi-omics mechanisms of tumourigenesis and progression, studies of tumour heterogeneity and drug resistance, and the development and optimisation of novel immune checkpoint inhibitors and CAR-T cell therapies.
The journal also focuses on translational medicine and therapeutic development, exploring targeted drug screening and artificial intelligence-driven drug design. Featured sections such as Cancer Landscapes and Computational Cancer Biology focus on the tumour microenvironment and the application of AI in cancer prediction.VICR looks forward to providing new perspectives and solutions for global cancer research and advancing the scientific community in the study of viral carcinogenesis.

The research topics of VICR include but are not limited to:
● Mechanisms of viral carcinogenesis
● Disruption of host genome stability by viral genes (HPV-E6/E7, EBV-LMP1, HBV-X
protein)
● Chronic Inflammation and Viral Persistent Infection Driven Cancer Processes
● Clinical and Translational Research
● Early diagnostic marker development for virus-associated cancers
● Synergistic application of antiviral therapies (e.g. mRNA vaccines, CRISPR-Cas9 editing)
with immunotherapy
● Engineering innovation of viral vectors in gene therapy.
● Public Health and Policy
● Global HPV vaccination coverage and cancer incidence correlation study
● Epidemiological modelling of viral carcinogenesis and prevention and control strategies.
● Cancer Biology
● Cancer Immunology
● Cancer Metabolism and Molecular Mechanisms
● Therapeutic Development and Chemical Biology
● Translational Cancer Biology
● Cancer Landscapes
● Computational Cancer Biology and Technology
● Convergence Science

The article processing charges is $800 per article.